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Abstract
Background: Mapping the expression changes during breast cancer development should facilitate basic and translational
research that will eventually improve our understanding and clinical management of cancer. However, most studies in this
area are challenged by genetic and environmental heterogeneities associated with cancer.
Methodology/Principal Findings: We conducted proteomics of the MCF10AT breast cancer model, which comprises of 4
isogenic xenograft-derived human cell lines that mimic different stages of breast cancer progression, using iTRAQ-based
tandem mass spectrometry. Of more than 1200 proteins detected, 98 proteins representing at least 20 molecular function
groups including kinases, proteases, adhesion, calcium binding and cytoskeletal proteins were found to display significant
expression changes across the MCF10AT model. The number of proteins that showed different expression levels increased
as disease progressed from AT1k pre-neoplastic cells to low grade CA1h cancer cells and high grade cancer cells.
Bioinformatics revealed that MCF10AT model of breast cancer progression is associated with a major re-programming in
metabolism, one of the first identified biochemical hallmarks of tumor cells (the ‘‘Warburg effect’’). Aberrant expression of 3
novel breast cancer-associated proteins namely AK1, ATOX1 and HIST1H2BM were subsequently validated via
immunoblotting of the MCF10AT model and immunohistochemistry of progressive clinical breast cancer lesions.
Conclusion/Significance: The information generated by this study should serve as a useful reference for future basic and
translational cancer research. Dysregulation of ATOX1, AK1 and HIST1HB2M could be detected as early as the pre-neoplastic
stage. The findings have implications on early detection and stratification of patients for adjuvant therapy.
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Introduction
Cancer is the result of a multi-step process involving initiation,
propagation and maintenance of cancer cells. Each individual step
and its transition to the next require accumulation of aberrations
associated with an intricate network of genes. A better understand-
ing of the molecular etiology and therefore a more effective
management of breast cancer requires a systems biology approach
as opposed to the classical one gene/one pathway approach. The
use of various genomics, proteomics technology platforms and
biological systems has provided much insight into these areas [1].
However, understanding disease progression is not without
challenges. For example, the study of clinical samples is complicated
by cellular, genetic, environmental and treatment heterogeneities.
On the other hand, it is difficult to ascertain whether changes
observed were indeed associated with cancer or due to variations in
genetic backgrounds when using non-isogenic in vitro cell models.
Isogenic cell lines are advantageous and have been used widely for
studying molecular events during disease development and drug
resistance.FirstdevelopedinFredMiller’slaboratory,theMCF10AT
model comprises at least four isogenic cell lines MCF10A1,
MCF10AT1K.cl2, MCF10CA1h and MCF10CA1a.cl1 that repre-
sent normal, premalignant epithelium, low grade and high grade
lesions, respectively [2,3]. MCF10A1 cells are not tumorigenic in
nude mice while MCF10AT1K.cl2 cells could form simple ducts that
progress into benign hyperplasia and occasionally carcinoma.
MCF10CA1h formed largely well differentiated carcinoma while
MCF10CA1a.cl1 produced poorly differentiated carcinoma and
could metastasize to the lung in tail vein injection assay. The
MCF10AT model has several salient features of proliferative breast
disease in humans including the histological spectrum of lesions and
heterogeneity within a single host [4]. This model has proven to be
useful for cancer related studies including cytogenetics, DNA
damage, apoptosis and TGF-b signaling [5,6,7,8].
Recently, mRNA expression profiling and copy number
variation of the MCF10AT model were conducted [9,10].
However, the mRNA level, copy number and protein level do
not necessarily correlate well. Since proteins are the workhorses of
the cells and .90% of all drug targets are protein in nature, we
proposed that proteomic analysis of the MCF10AT model is
complementary and informative. Although current proteome-wide
technologies could only detect a few thousand proteins at best,
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generate a useful reference database for future basic and
translational cancer research.
Several technologies that emerged at the turn of the millennium
are available for shot-gun protein expression profiling. They
include isotope-coded affinity tag (ICAT), isobaric tags for relative
and absolute quantification (iTRAQ) and stable isotope labeling
with amino acids in cell culture (SILAC) and have been reviewed
elsewhere [11,12]. Among them iTRAQ is a powerful tool in
which up to eight samples can be relatively quantified in one
experiment thereby reducing inconsistency between analyses [13].
In this study, iTRAQ was used to generate a list of proteins that
display expression changes during breast cancer progression as
modeled by the MCF10AT system. Subsequent studies validated
the aberrant expressions of some candidate proteins in the
progression of clinical breast cancers.
Materials and Methods
Reagents
Anti-mouse IgG (whole molecule), anti-rabbit IgG (whole
molecule) and Cy3-conjugated anti-Vimentin antibodies were
purchased from Sigma Chemical Co. (St. Louis, MO). Anti-
ATOX1 mouse monoclonal antibodies, anti-VCP and anti-
Histone H2B antibodies were from Abcam (Cambridge, UK).
Anti-AK1, anti-LGALS3 rabbit polyclonal antibodies and HRP-
conjugated anti-actin mouse monoclonal antibodies were from
Santa Cruz Biotechnology Inc. (CA, USA).
Cell lines, sample preparation and immunoblotting
Xenograft-derived breast cancer cell lines (MCF10A1,
MCF10AT1KCl.2, MCF10CA1h and MCF10CA1aCl.1) were
obtained from Dr Fred Miller at the Barbara Ann Karmanos
Cancer Institute (Detroit, MI). This biological system has been
extensively reviewed [14,15,16] and cell lines are cultured as
described in many studies [5,6,7,8,9,10]. Cells were incubated at
37uC in a humidified atmosphere containing 5% CO2 until 95%
confluence when the medium was replaced with serum- and
additives-free media overnight to study the basal protein expression.
Cells were rinsed with ice-cold PBS and lysed on ice for protein
extraction using iTRAQ lysis buffer: 0.2% IGEPAL, 0.2% Triton
X, 0.2% w/v CHAPS, 75 mM NaCl, 1 mM EDTA, 50 mM
sodium fluoride, protease inhibitor and 1 mM sodium orthovana-
date in PBS. Protein lysates were then clarified by centrifugation at
4uC at 14,000 rpm for 10 min. Total protein was determined using
the bicinchoninic acid assay (BCA) kit (Pierce Biotechnology).
Immunoblotting was performed as per previous reports [17,18].
Isobaric peptide labeling and nanoLC-MS/MS analysis
A total of 100 mg of protein from each sample was reduced,
alkylated, digested and labeled with iTRAQ reagents according to
the manufacturer’s protocol (Applied Biosystems, Framingham, MA,
USA). Specifically, proteins from MCF10A1, MCF10AT1k.cl2,
MCF10CA1h and MCF10CA1a.cl1cells were labeled with 114,
115, 116 and 117 tags respectively. The dried, labeled peptides were
then constituted and subject to ion exchange chromatography as
previously described[19]. A total of 23 fractions were collected and
these fractions were dried in vacuum concentrator, and stored at
220uC prior to mass spectrometric analysis. Mass spectrometry was
performed using a QStar XL Hybrid ESI Quadrupole time-of-flight
tandem mass spectrometer, electrospray ionization quadruple-time of
flight tandem-mass spectrometry (ESI-qQ-TOF-MS/MS) (Applied
Biosystems, Framingham, MA, USA; MDS-Sciex, Concord, On-
tario, Canada) coupled with an online nanoflow liquid chromato-
graph (Agilent 1100 system from Agilent, Santa Clara, USA). Protein
identification and quantification for iTRAQ samples were carried out
using ProteinPilot
TM software (version 2.0; Applied Biosystems,
MDS-Sciex). Only proteins identified with at least 95% confidence
i.e., p#0.05were reported. Other detailswere as previouslydescribed
[19]. To estimate the rate of false positive in the dataset obtained, we
employed a database search strategy against a concatenated pseudo-
reverse database [20]. This database was created in-house, consisting
16,602 human sequences and their pseudo reverse sequences. Here
we defined FDR as the percentage of decoy proteins identified against
the total protein identification.
Immunofluorescence
Cells were grown on Menzel microscope coverslip till about 50–
60% confluence. The coverslip was rinsed in three changes of
PBS, pH 7.4 and fixed with 3.7% paraformaldehyde, permeabi-
lized in PBS containing 0.5% Triton X. Following blocking with
1% BSA, cells were incubated with Cy3-conjugated anti-Vimentin
mouse monoclonal antibody (1:1000 dilution) at 37uC for 1 h.
After washing 3 times with PBST (PBS+0.1% Tween 20) for 3 min
each, cells were counterstained with DAPI for 1 minute. Cells were
then mounted on glass slide with prolong anti-fade reagent.
Analyses were done using Zeiss dark field fluorescence microscope
with barrier filter 50, interference filter KP-500, and a 100-W
quartz Halogen lamp light source was used.
Clinical samples and Immunohistochemistry
Frozen matched malignant and adjacent normal breast tissues
were requested from the Tissue Repositories (TRs) of NCCS and
NUH (retrospective accrual) following approvals from Institutional
Review Boards from the National Cancer Centre of Singapore
(NCCS), National University Hospital (NUH) and the National
University of Singapore. They are mainly primary tumors and they
were stored in liquid nitrogen before use. We have no information
on the treatment history of these samples. Frozen tissues were
prepared for IHC by first fixing them in 10% neutral buffered
formalin (Sigma) for 16 h at 4uC, subject to ThermoShandon tissue
processor and embedded in paraffin. Paraffin sections were warmed
in a 60uC oven and dewaxed in three changes of xylene and
passaged through graded ethanol (100%, 95%, 70%) before a final
wash in ddH20. For ATOX1, antigen retrieval was performed via
pressure cooking at 120uC for 5 min in Tris-EDTA buffer, pH 9.0.
For HIST1H2BM and AK1, antigen retrieval was performed using
the Target Retrieval Solution (Dakocytomation, Denmark) at 95uC
for 40 min. After quenching of endogenous peroxidase activity with
3% H202 for 10 min and blocking with 5% BSA for 30 min,
sections were incubated at 4uC for overnight with antibodies against
the primary antibodies at 1:25 to 1:100 dilutions. Detection was
achieved with the Envision+/HRP system (Dakocytomation, Den-
mark). All slides were counterstained with Gill’s hematoxylin for
1 min, dehydrated and mounted for light microscopic evaluation.
IHC scoring and statistical analyses
Interpretation of H&E sections and analysis/scoring of IHC
data were all done by certified pathologists (NS). Expression of
proteins revealed by IHC was first scored (3+=3,2+=2,1+=1,
0=negative; NA=scores not available due to lack of ductal
components). In cases where different degrees of staining were
observed within the same section, average values were taken e.g.
2+/1+=1.5. Where staining was observed only for certain areas
within the section, the entire section was surveyed to estimate the
percentage of area with positive signal. Hence for scores with
percentage within parenthesis, e.g. 2+ (50%), the final score was
obtained by the multiplying 260.5=1.0.
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Detection and relative quantification of proteins across
the MCF10AT model of breast cancer progression
The cell lines used in this study MCF10A1, MCF10AT1K.cl2,
MCF10CA1h and MCF10CA1a.cl1 are abbreviated as A1, 1k, 1h
and 1a, respectively. In our laboratory, the tumors obtained by
subcutaneous injection of 1k, 1h, and 1a cancer cells into nude
mice grew at different rates and were of increasing grades (degree
of differentiation) as assessed by our pathologist (NS) validating
that the model was indeed reflective of disease progression as
originally reported by Miller’s group [21]. The experimental
design is shown in Figure 1. Two biological preparations were
made and analyzed independently to achieve greater accuracy.
Following analysis with ProteinPilot
TM software, .1000 proteins
were detected with 95% confidence and the relative expression
levels of proteins determined as iTRAQ ratios.
To filter out proteins that display high confidence expression
changes across the MCF10AT model, we performed a 2-step data
processing. First, we implemented a 1.3 fold cut off on the iTRAQ
ratios to segregate proteins into those that were up or down
regulated. This cut-off value was applied since several iTRAQ
studies conducted in our laboratory revealed that the technical
variation was consistently below 30%. Therefore, the upper and
lower range worked out to be 1.3 (161.3) and 0.77 (1/1.3),
respectively. Proteins with expression ratios below the lower range
were considered to be under-expressed while those above the higher
range were considered over-expressed. Second, only iTRAQ ratios
that fulfilled the 1.3 fold criteria AND are statistically significant
ratios arehighlighted in red (for up-regulation) and green (for down-
regulation). This resulted in Supplementary Table S1, which shows
98 proteins with significant difference in expression level across one
or more stages of breast cancer progression as modeled by the
MCF10AT system. The protein detection (including group
reporting and% coverage) and other relative quantification data
including p-value, error factor (EF) and% coverage from iTRAQ/
ESI-based LC-MS/MS analyses are provided as Supplementary
Table S2. The false discovery rate (FDR) for iTRAQ/ESI-based
data worked out to be 1.2%.
Characteristics of the proteomic changes across the
MCF10AT model
From Supplementary Table S1, we observed that the number of
proteins that showed different expression levels increased as
disease progressed from AT1k pre-neoplastic cells to low grade
CA1h cancer cells and high grade cancer cells. This reflects an
immense degree of aberrations when cancer transit from low to
high grade cancers. Since this study represents the first proteome-
wide analysis of the MCF10AT model of breast cancer
progression, it was necessary to understand the nature of the
proteins involved in the process. To this end, 98 proteins were
classified via KO (KEGG Orthology) using KEGG pathway
database [22,23]. Figure 2A shows that cancer progression is
associated with a major re-programming in metabolism (42%), one
of the first identified biochemical hallmarks of tumor cells (the
‘‘Warburg effect’’). To characterize the functions associated with
proteins detected, the gene list was uploaded into Ingenuity
Pathways Analysis (IPA) software server and analyzed using the
Core Analysis module as per manufacturer’s instructions [24]. As
seen in Figure 2B, the top two functions that the gene list is most
significantly related to is cancer and cell death. This suggests that
the list of genes detected in this study is mostly regulators/effectors
of cancer cell growth and proliferation.
Major classes of proteins implicated in the MCF10AT
model of breast cancer development
To organize the data in Supplementary Table S1, proteins were
classified into their respective molecular functions using PAN-
THER [25]. Supplementary Table S3 shows the classification of
98 proteins into the various molecular functions. A few molecular
function classes associated with the salient phenotypes of cancer
were selected for discussion.
(A) Calcium-binding proteins. Calcium is an important
secondary messenger and proteins that regulate calcium fluxes or
whose functions are regulated by calcium are important regulators
of cancer cell biology [26]. The S100 family of proteins has at least
25 members, most containing 2 EF-hand calcium binding motifs.
They have been shown to play diverse roles ranging from
regulation of calcium release, microtubule assembly and signaling
pathways [27]. Close to ten S100 calcium-binding proteins were
detected in our dataset. Aberrant expressions of these proteins
have been implicated in the pathogenesis of many human cancers
with some members (e.g. A100A4 and A8) being associated with
cancer invasiveness and metastasis [28,29]. Consistent with the
DNA microarray analysis of the MCF10AT system [9], S100A8
and S100A9 were found to be down-regulated in our study. In
addition, we have identified up-regulation of several other S100
proteins including A2, A11, A13, A14 and A16, abnormal
expressions of which have been associated with bladder and
esophageal carcinomas [30,31].
(B) Cytoskeletal proteins. Transition of cancer cells from
non-invasive to invasive phenotype is usually accompanied by
Figure 1. Overview of iTRAQ-based protein expression profiling of MCF10AT breast cancer progression model. Biological duplicates
were prepared. Lysates from A1, 1k, 1h and 1a cells were labeled with 114, 115, 116 and 117 iTRAQ isotopic labels, respectively, and analyzed with
nanospray-ESI tandem mass spectrometry.
doi:10.1371/journal.pone.0011030.g001
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with EMT is enhanced migratory capacity. Interestingly, Vimentin,
an intermediate filament cytoskeletal protein and a marker of EMT
was shown by this study to be significantly up-regulated in CA1a high
grade cancer cells. Asthe Vimentinantibodieswepurchased werenot
good for immunoblotting, we performed immunofluorescence of
Vimentin (VIM) across the MCF10AT cells lines. Highly invasive
MDA-MB-231 (231) cell line was included as a control. Although IF
is only semi-quantitative, it clearly revealed very strong Vimentin
expression in CA1a high grade cancer cells compared to 10A1
normal mammary epithelial cells (Figure 3A). Like MDA-MD-231,
CA1a cells displayed a more fibroblastic morphology that is
characteristic of highly migratory cells, compared to the rest of the
cell lines. Intermediate filaments are important to cell migration,
invasion and metastasis [32]. They extend from the nucleus to the
internal leaflet of the plasma membrane and because they are
connected to the extracellular matrix via the integrins, they are
components of an intrinsic system that regulate the mechanical
properties of cells during cellular processes such as cell movement.
Other prominent members of the intermediate filaments include the
cytokeratins. Overexpression of cytokeratins such as KRT8 was
shown to enhance adhesion of MCF7 cells to the extracellular matrix
Figure 2. Functional characterization of proteins detected to display aberrant expression across the MCF10AT model of breast
cancer progression. (A) Proteins were organized via KO (KEGG Orthology) using KEGG pathway database into major processes such as Metabolism
(carbohydrate, lipid, amino acid etc.); Genetic Information Processing (transcription, translation, replication, repair etc.); Environmental Information
Processing (membrane transport, signal transduction etc.); and Cellular Processes (cell growth, death, motility etc.). (B) Gene list was imported and
analyzed by the Core Analysis Module in Ingenuity Pathway Analysis software to statistically determine the functions/pathways most strongly
associated with the gene list.
doi:10.1371/journal.pone.0011030.g002
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Godfroid et. al. further demonstrated the presence of cytokeratins
K R T 8 ,K R T 1 8 ,a n dK R T 1 9o nt h eo u t e rs u r f a c eo fe s t a b l i s h e d
human mammary carcinoma cells but not normal mammary
cells[34]. In this study, up-regulation of Keratin 17 (KRT17) and
down-regulation of Keratin 15 (KRT15) were observed in breast
cancer. While there is little information on the role of KRT15 in
breast cancer, KRT17 expression was studied in 600 breast tumors
and was shown to be associated with poor clinical outcome [35].
(C) Focal and Cell adhesion and proteins. Assembly and
disassembly of cytoskeletal proteins at focal adhesions are
important steps during cellular movement. In line with the
observation of aberrant expression of proteins associated with
EMT and increased migratory potential, proteins such as Vinculin
and Integrin A6 (ITGA6) that are involved in the regulation of
focal adhesion were also found to be up-regulated. Furthermore,
ITGA6 has been shown to be necessary for tumorigenesis of stem
cell subpopulation derived from MCF7 cell line [36]. On the other
hand, Galectin 3, a cell adhesion molecule, was detected to down-
regulated in AT1K pre-neoplastic, CA1h low- and CA1a high-
grade cancer cell lines compared to normal cells. This not
surprising since cell-to-cell adhesion needs to be reduced in order
for cancer cells to break apart and migrate. The ITRAQ data was
confirmed by immunoblotting (Figure 3B) and is consistent with
another study that described detectable expression of Galectin 3 in
normal ducts and down-regulation in ductal carcinoma in situ [37].
(D) Others. Proteasomes are important for controlling the
expressions of many proteins, one of the most prominent groups
being the cell cycle regulating proteins. PSMB3 proteasome, which
cleave peptides in an ATP/ubiquitin-dependent process in a non-
lysosomal pathway, was found to be up-regulated in this study.
This concurs with the observation that PSMB3 was co-expressed
with ERBB2 in 34 breast cancer biopsies and also mapped within
the same chromosomal location as the ERBB2 gene that is
frequently amplified [38]. It is unclear how up-regulation of
PSMB3 expression contributes to cancer. Valosin-containing
protein is an ATPase that is involved in many cellular functions,
including regulating the S26 proteasome function and E3
ubiquitin-protein ligase activity of RNF19A. High level of VCP
expression in cancer cells has been shown to correlate with the
increase in recurrence rate and poor prognosis of patients with
cancer of the liver, stomach, prostate and esophagus [39]. A recent
study identified VCP as an essential target of oncogenic Akt
signaling and was necessary for cell growth and survival [40]. Up-
regulation of VCP in at least two abnormal cell lines in MCF10AT
model was confirmed by immunoblotting (Figure 3B).
Aberrant expressions of novel-breast cancer associated
proteins in vitro and ex-vivo
From extensive literature search, AK1, ATOX1 and
HIST1H2BM were among the few whose aberrant expressions
have not been previously associated with breast cancer develop-
ment. Therefore, we proceeded to conduct immunoblotting to
examine the relative expression levels of these proteins in the
MCF10AT model. The immunoblotting data and the densitom-
etry values of the protein bands as well as the predominant
expression trend of the proteins across the MCF10AT model are
shown in Figure 4A, left panel. The proteins AK1 and ATOX1
showed up-regulation in one or more aberrant cell lines compared
to A1 normal cells, while expression of HIST1H2BM was
Figure 3. Expression profiles of Vimentin, LGALS3 and VCP across the MCF10AT model. (A) Immunofluorescence of Vimentin in
MCF10AT model using Cy3-conjugated anti-Vimentin antibodies. (B) Top panels - Immunoblotting of LGALS3 and VCP. Cells were processed as per
iTRAQ experiments. The lysates were immunoblotted with the protein-specific antibodies to reveal the relative expression levels across the 4
MCF10AT cell lines. Actin was included as a loading control. Bottom panel -Densitometry readings for the signals corresponding to the respective
protein bands were obtained and expressed as a ratio using the signal from A1 normal cells as the denominator
doi:10.1371/journal.pone.0011030.g003
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the absolute expression ratios generated by iTRAQ and
immunoblotting methods are not the same, the expression trends
reflected by both methods were congruent and confirmed the
aberrant expressions of candidate proteins across the MCF10AT
model of disease progression.
A major limitation of in vitro models like MCF10AT is that these
systems lack the physiological context present in the human body.
Consequently, we examined their expressions in 26 matched cases
of clinical samples. From the immunohistochemistry studies,
increased expression from matched normal to DCIS (ductal
carcinoma in situ) and IDC (invasive ductal carcinoma) were
observed for AK1 (8/21 or 38% of all cases) and ATOX1 (10/19 or
53% of all cases) (Figure 4B, lower panel). In contrast, decreased
expression across progressive lesions was observed for
HIST1H2BM in 20% (4/20) of all cases. Note that a significantly
smaller frequency of opposite trend existed for most protein
candidates, reflecting molecular heterogeneity of breast cancers.
The raw IHC scores for the various candidate proteins are provided
in Supplementary Table S4. One representative case of IHC data
showing the predominant expression trend (up or down) for each
candidate protein is shown in Figure 4B, upper panel. From the
IHC data, the predominant localization of the candidate proteins
could be summarized as: AK1–cytoplasmic and nuclear; ATOX1–
cytoplasmic and nuclear; HIST1H2BM–nuclear. The observed
localizations of these proteins are largely consistent with those
reported in the literature or public databases such as GeneCardsH.
Discussion
This study represents the first proteome-wide approach to study
the MCF10AT model of breast cancer progression. A DNA
microarray study has been conducted recently on this model and
some members in the S100 family were found to be down-
regulated while Kallikrein and Thrombospondin were up-
regulated [9]. In another study, array comparative genomic
hybridization detected amplification of Myc and deletion of Runx
1, LRP1B, CDH13 and FHIT genes [10]. Due to the different
nature of analytical methods used, these datasets largely do not
overlap with ours, reiterating the complementary nature of
proteomics and genomic approaches.
Using stable isotope/liquid chromatography-based mass spec-
trometry, we obtained the expression profiles of more than 1200
proteins in the MCF10AT model of breast cancer progression.
The molecular changes detected suggest that cellular transforma-
tion and acquisition of aggressive phenotype involves ‘‘re-
programming’’ of cellular systems, especially in processes associ-
ated with carbohydrate, amino acid and lipid metabolism. This is
perhaps not surprising since metabolism is an Achilles’ heel in
cancer biology [41]; For instance, aberrant PI3K/AKT pathway
during cancer development inadvertently amplifies glucose
metabolism and translational activities via glucose transporter
(GLUT4), mTOR/S6K/eukaryotic initiation factor 4E-binding
protein 1 (4EBP-1), respectively [42,43]. Consistently, several
translation initiation factors were observed to be up-regulated in
this study.
ATOX1, AK1 and HIST1H2BM have been validated as novel-
breast cancer associated proteins. Among these, ATOX1 is most
outstanding since its expression was higher in tumor compared to
normal tissues in 53% (out of 19 cases) of matched clinical samples
analyzed. ATOX1 was recently demonstrated to be a copper
dependent transcriptional factor involved in cell proliferation [44].
Depletion of copper has been shown to inhibit angiogenesis in a
variety of cancer and xenograft systems [45]. Several clinical trials
Figure 4. Validation of the expression of novel breast cancer-associated proteins AK1, ATOX1 and HIST1H2BM in vitro and ex-vivo. (A)
Top panels, Immunoblotting of ATOX1, AK1 and HIST1H2BM. Cells were processed as per iTRAQ experiments. The lysates were immunoblotted with
the protein-specific antibodies to reveal the relative expression levels across the 4 MCF10AT cell lines. Actin was included as a loading control. Bottom
panel, Densitometry readings for the signals corresponding to the respective protein bands were obtained and expressed as a ratio using the signal
from A1 normal cells as the denominator. (B) Immunohistochemistry of ATOX1, AK1 and HIST1H2BM were performed on 26 matched adjacent normal
and tumor tissues containing a spectrum of lesions including DCIS and IDC. Top panels-A representative case showing the predominant expression
trend for each candidate is shown. Bottom panel–Summary of the expression trends of candidate proteins between normal and breast cancer lesions.
doi:10.1371/journal.pone.0011030.g004
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have also been conducted [46]. It would be interesting to conduct
further studies on ATOX1 that should provide new insights into
the role and mechanism of ATOX1 in breast cancer biology.
The MCF10AT model is unlikely to reflect all the molecular
changes associated with clinical breast cancers since it is an in vitro
model. Besides, the isogenic cell lines in the MCF10AT model
probably represent only one of the evolutionary tracks during
tumorigenesis and do not encompass the entire spectrum of
heterogeneity associated with breast cancers. Therefore, technical
and/or biological factors therefore are likely to limit the resolution
and the representativeness of the data presented in this study.
Nevertheless, with these caveats in mind and appropriate
validation steps taken, the mini-catalogue of protein expression
changes should serve as a good reference/guide for future basic
and translational cancer research. For example, not all cases of
DCIS progress to carcinoma and whether all patients with DCIS
should receive adjuvant therapy after breast-conserving surgery
remains a topic of active debate [47]. Detection of the aberrant
expression of ATOX1 and AK1 in pre-neoplastic cells (DCIS and
AT1k cells) and the relatively higher expression of the two proteins
in breast carcinoma compared to normal tissues suggest that they
could be involved in cancer initiation and progression for at least a
subset of breast cancers. It is conceivable that they could serve as
molecular markers in determining the risk of DCIS developing
local recurrence or invasive carcinoma and therefore help select
patients for adjuvant therapy. On the other hand, proteins
involved the later stages of cancer development might be
important for disease maintenance/aggression and are potential
prognostic factors and/or drug targets.
In conclusion, the information generated by this study should be
a useful reference for future basic and translational cancer
research. In turn, subsequent follow-up studies would eventually
decipher which genes are cancer-driving and which are just
passengers, thereby advancing our knowledge of breast cancer
biology.
Supporting Information
Table S1 Proteins with statistically significant expression
changes across the MCF10AT model.
Found at: doi:10.1371/journal.pone.0011030.s001 (0.06 MB
XLS)
Table S2 Protein summary generated by ProteinPilot following
mass spectrometry analysis.
Found at: doi:10.1371/journal.pone.0011030.s002 (0.52 MB
XLS)
Table S3 Classification of the proteins identified in the
MCF10AT model into molecular functions using the PANTHER
(http://www.pantherdb.org/).
Found at: doi:10.1371/journal.pone.0011030.s003 (0.03 MB
XLS)
Table S4 Raw IHC scores for candidate proteins in clinical
breast samples.
Found at: doi:10.1371/journal.pone.0011030.s004 (0.04 MB
XLS)
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